Literature DB >> 28884747

Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.

Manuel D Keller1, Christina Neppl1, Yasin Irmak1, Sean R Hall2,3, Ralph A Schmid2,3, Rupert Langer1, Sabina Berezowska1.   

Abstract

Immunohistochemical assessment of programmed cell death (PD)-ligand 1 (PD-L1) expression in lung cancer in the context of therapeutically targeting the PD1/PD-L1 axis is still controversially discussed. This includes the comparability of antibody clones, prognostic value, and discrepancies between primary tumors and metastases. We assessed tumoral PD-L1 expression using clones E1L3N and SP142 in 372 primary resected pulmonary squamous cell carcinomas, including 40 paired N2 lymph node metastases, in relation with clinico-pathological parameters. PD-L1 expression was negative (<1%) in 163/372 (44%, E1L3N) or 231/370 patients (62%, SP142). Positivity of 1-<50% was observed in 135 (36%, E1L3N) or 92 patients (25%, SP142) and ≥50% in 74 (20%, E1L3N) or 47 patients (13%, SP142). PD-L1 staining correlated significantly between both antibodies (r=0.781; P<0.001). Scores correlated significantly between full-slide sections (N=40) and tissue microarrays, and between primaries and N2 metastases (P<0.001 all). CD8+ tumor infiltrating lymphocyte counts positively correlated with PD-L1 expression (P<0.001). PD-L1 ≥50% showed the best prognostic discrimination using the split-sample validation method. It was associated with shorter disease-specific survival in the observation group (E1L3N: P=0.035, SP142: P=0.002) and validation group (E1L3N: P=0.024, SP142: P=0.101) and shorter time to recurrence (observation group: E1L3N: P=0.056, SP142: P<0.001; validation group: E1L3N: P=0.036, SP142: P=0.247). Multivariate analysis showed that PD-L1 expression ≥50% determined by clone E1L3N was an independent prognostic factor in the observation group regarding disease-specific survival (HR=2.768; 95% CI=1.149-6.666; P=0.023) and time to recurrence (HR=2.164; 95% CI=1.056-4.436; P=0.035) and in the validation group (disease-specific survival: HR=1.978; 95% CI=0.928-4.214; P=0.077 and time to recurrence: HR=1.571; 95% CI=0.838-2.944; P=0.159). High PD-L1 expression was associated with adverse prognosis in pulmonary squamous cell carcinoma. Clone E1L3N was more sensitive than SP142 and superior regarding prognostication. PD-L1 expression correlated significantly between primary tumor and N2 metastases, rendering mediastinal lymph node metastases adequate for immunohistochemical assessment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28884747     DOI: 10.1038/modpathol.2017.111

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  30 in total

1.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

Review 2.  Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.

Authors:  Keith M Kerr; Marianne C Nicolson
Journal:  Arch Pathol Lab Med       Date:  2016-03       Impact factor: 5.534

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.

Authors:  Thomas J Gniadek; Qing Kay Li; Ellen Tully; Samit Chatterjee; Sridhar Nimmagadda; Edward Gabrielson
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

5.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

Authors:  Daniel S Chen; Bryan A Irving; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531

8.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Authors:  Andreas H Scheel; Manfred Dietel; Lukas C Heukamp; Korinna Jöhrens; Thomas Kirchner; Simone Reu; Josef Rüschoff; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Arne Warth; Wilko Weichert; Rieke N Fischer; Jürgen Wolf; Reinhard Buettner
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

9.  Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.

Authors:  Jamaal A Rehman; Gang Han; Daniel E Carvajal-Hausdorf; Brad E Wasserman; Vasiliki Pelekanou; Nikita L Mani; Joseph McLaughlin; Kurt A Schalper; David L Rimm
Journal:  Mod Pathol       Date:  2016-11-11       Impact factor: 7.842

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

View more
  12 in total

Review 1.  Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.

Authors:  Sylvie Lantuejoul; Francesca Damiola; Julien Adam
Journal:  Transl Lung Cancer Res       Date:  2020-06

2.  High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.

Authors:  Boyang Chang; Lujun Shen; Kefeng Wang; Jietian Jin; Tao Huang; Qifeng Chen; Wang Li; Peihong Wu
Journal:  Liver Int       Date:  2018-02-13       Impact factor: 5.828

3.  Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas.

Authors:  Rupert Langer; Christina Neppl; Manuel D Keller; Ralph A Schmid; Mario P Tschan; Sabina Berezowska
Journal:  Cancers (Basel)       Date:  2018-08-21       Impact factor: 6.639

4.  The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.

Authors:  Sarah Rosanne Ottenhof; Rosa Sanne Djajadiningrat; Helene Hoegsbro Thygesen; Pamela Josephine Jakobs; Katarzyna Jóźwiak; Anne Marijne Heeren; Jeroen de Jong; Joyce Sanders; Simon Horenblas; Ekaterina Straschimirova Jordanova
Journal:  Front Immunol       Date:  2018-06-11       Impact factor: 7.561

5.  The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yan Li; Qingying Huang; Yaoyao Zhou; Meizhi He; Jianhong Chen; Yubo Gao; Xue Wang
Journal:  Front Pharmacol       Date:  2019-01-24       Impact factor: 5.810

6.  A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.

Authors:  Cheng Lu; Kaustav Bera; Xiangxue Wang; Prateek Prasanna; Jun Xu; Andrew Janowczyk; Niha Beig; Michael Yang; Pingfu Fu; James Lewis; Humberto Choi; Ralph A Schmid; Sabina Berezowska; Kurt Schalper; David Rimm; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Lancet Digit Health       Date:  2020-10-19

7.  PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3.

Authors:  Daozhi Xu; Peixin Dong; Ying Xiong; Rui Chen; Yosuke Konno; Kei Ihira; Junming Yue; Hidemichi Watari
Journal:  Front Cell Dev Biol       Date:  2020-12-09

8.  [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].

Authors:  Qingqing Hang; Hangjie Ying; Guoping Cheng; Shifeng Yang; Jianan Jin; Yamei Chen; Qixun Chen; Youhua Jiang; Qiang Zhao; Min Fang; Ming Chen; Xiaojing Lai
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-10-20

9.  Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.

Authors:  Bregje M Koomen; Sushil K Badrising; Michel M van den Heuvel; Stefan M Willems
Journal:  Histopathology       Date:  2020-03-24       Impact factor: 5.087

10.  Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung.

Authors:  Tereza Losmanová; Félice A Janser; Magali Humbert; Igor Tokarchuk; Anna M Schläfli; Christina Neppl; Ralph A Schmid; Mario P Tschan; Rupert Langer; Sabina Berezowska
Journal:  Oxid Med Cell Longev       Date:  2020-09-21       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.